WASHINGTON, March 24 (UPI) -- A U.S. Food and Drug Administration advisory panel has approved a therapy to reduce mortality and heart failure risk in patients with mild cardiac disease.
The FDA panel recommended the cardiac resynchronization therapy defibrillator be approved for use in patients with mild heart failure. The device was tested in a series of nationwide studies led by Dr. Arthur Moss, professor of medicine at the University of Rochester Medical Center.
Developed by the Boston Scientific Corp., the defibrillator was previously approved to treat patients with severe heart failure.
The FDA often, but not always, follows the recommendations of its advisory panels.